# BPGM

## Overview
The BPGM gene encodes the enzyme bisphosphoglycerate mutase, which is primarily expressed in human erythrocytes. This enzyme is a key regulator in the Rapoport-Luebering shunt, a glycolytic pathway that modulates the levels of 2,3-bisphosphoglycerate (2,3-BPG) in red blood cells. As a multifunctional enzyme, bisphosphoglycerate mutase exhibits both synthase and phosphatase activities, crucial for the isomerization of 1,3-bisphosphoglycerate to 2,3-BPG, and the conversion of 2,3-BPG to 3-phosphoglycerate, respectively. The regulation of 2,3-BPG is vital for its role as an allosteric effector of hemoglobin, influencing oxygen release to tissues. Structurally, bisphosphoglycerate mutase is a homodimeric enzyme with a complex α/β protein structure, and its activity is modulated by post-translational modifications such as phosphorylation. Mutations in the BPGM gene can lead to clinical conditions like erythrocytosis, highlighting its importance in maintaining normal oxygen transport and delivery (Lemarchandel1992Compound; Ravel1997Critical; Aljahdali2022Molecular).

## Structure
Bisphosphoglycerate mutase (BPGM) is a homodimeric enzyme, with each monomer consisting of 259 amino acids (Aljahdali2022Molecular). The primary structure of BPGM includes several key residues, such as Cys22, Ser23, and Arg89, which are crucial for its enzymatic activity and substrate binding (Ravel1997Critical). The secondary structure of BPGM is characterized by an α/β protein structure, as indicated by circular dichroism spectroscopy (Ravel1997Critical).

The tertiary structure of BPGM involves a three-dimensional folding that is stabilized by interactions among its amino acids. The enzyme's active sites are located in the C-terminal portion of each monomer, with specific residues like Arg100, Arg116, and Arg117 playing significant roles in substrate interaction and stabilization of the active site in a closed conformation necessary for catalysis (Aljahdali2022Molecular). The quaternary structure of BPGM is a stable dimeric form, as confirmed by analytical ultracentrifugation experiments (Aljahdali2022Molecular).

BPGM also undergoes post-translational modifications, such as phosphorylation, which can affect its activity and stability (Craescu1992Structural). These structural features are essential for BPGM's function in regulating 2,3-bisphosphoglycerate levels in erythrocytes.

## Function
Bisphosphoglycerate mutase (BPGM) is a multifunctional enzyme predominantly found in human erythrocytes, where it plays a crucial role in the Rapoport-Luebering shunt, a side pathway of glycolysis. BPGM is responsible for the regulation of 2,3-bisphosphoglycerate (2,3-BPG) levels in red blood cells through its synthase and phosphatase activities. The enzyme's primary function is the isomerization of 1,3-bisphosphoglycerate to 2,3-BPG, which acts as an allosteric effector of hemoglobin, decreasing its affinity for oxygen and facilitating oxygen release to tissues (Aljahdali2022Molecular; Chu2014Insights).

In addition to its synthase activity, BPGM also catalyzes the conversion of 2,3-BPG to 3-phosphoglycerate through its phosphatase activity, although this activity is inherently low and is stimulated by anions such as 2-phosphoglycolate (Aljahdali2022Molecular). This regulation of 2,3-BPG levels is essential for the allosteric modulation of hemoglobin, optimizing oxygen delivery to tissues under varying physiological conditions (Joulin1988Isolation; Ravel1997Critical). The enzyme's activity is crucial for maintaining efficient oxygen transport and release, adapting to the body's oxygen demands (Aljahdali2022Molecular).

## Clinical Significance
Mutations in the BPGM gene can lead to erythrocytosis, a condition characterized by an increased number of red blood cells. This is often due to a deficiency in bisphosphoglycerate mutase (BPGM) activity, which results in decreased levels of 2,3-bisphosphoglycerate (2,3-BPG) in red blood cells. The reduced 2,3-BPG levels cause a leftward shift in the hemoglobin oxygen dissociation curve, increasing hemoglobin's oxygen affinity and leading to compensatory erythrocytosis (Rosa1989Isolation; Lemarchandel1992Compound).

Several specific mutations in the BPGM gene have been identified in association with erythrocytosis. These include the Arg 89 to Cys substitution, which results in an inactive enzyme and was one of the first mutations described in this context (Rosa1989Isolation; Lemarchandel1992Compound). Another mutation involves a leucine-to-proline substitution at codon 87, which also leads to erythrocytosis by affecting a highly conserved amino acid in the enzyme (Lazana2020Uniparental).

In some cases, compound heterozygosity involving different mutations in the BPGM gene has been observed, further contributing to the enzyme deficiency and the resultant clinical manifestations (Bento2013Genetic). These genetic alterations underscore the critical role of BPGM in maintaining normal red blood cell function and oxygen delivery.


## References


[1. (Bento2013Genetic) Celeste Bento, Melanie J. Percy, Betty Gardie, Tabita Magalhães Maia, Richard van Wijk, Silverio Perrotta, Fulvio Della Ragione, Helena Almeida, Cedric Rossi, François Girodon, Maria Åström, Drorit Neumann, Susanne Schnittger, Britta Landin, Milen Minkov, Maria Luigia Randi, Stéphane Richard, Nicole Casadevall, William Vainchenker, Susana Rives, Sylvie Hermouet, M. Leticia Ribeiro, Mary Frances McMullin, Holger Cario, Aurelie Chauveau, Anne-Paule Gimenez-Roqueplo, Brigitte Bressac-de-Paillerets, Didem Altindirek, Felipe Lorenzo, Frederic Lambert, Harlev Dan, Sophie Gad-Lapiteau, Ana Catarina Oliveira, Cédric Rossi, Cristina Fraga, Gennadiy Taradin, Guillermo Martin-Nuñez, Helena Vitória, Herrera Diaz Aguado, Jan Palmblad, Julia Vidán, Luis Relvas, Maria Leticia Ribeiro, Maria Luigi Larocca, Maria Luigia Randi, Maria Pedro Silveira, Melanie Percy, Mor Gross, Ricardo Marques da Costa, Soheir Beshara, Tal Ben-Ami, and Valérie Ugo. Genetic basis of congenital erythrocytosis: mutation update and online databases. Human Mutation, 35(1):15–26, October 2013. URL: http://dx.doi.org/10.1002/humu.22448, doi:10.1002/humu.22448. This article has 92 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.22448)

[2. (Craescu1992Structural) CT Craescu, O Schaad, MC Garel, R Rosa, and S Edelstein. Structural modeling of the human erythrocyte bisphosphoglycerate mutase. Biochimie, 74(6):519–526, June 1992. URL: http://dx.doi.org/10.1016/0300-9084(92)90149-9, doi:10.1016/0300-9084(92)90149-9. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/0300-9084(92)90149-9)

[3. (Joulin1988Isolation) V Joulin, M C Garel, P Le Boulch, C Valentin, R Rosa, J Rosa, and M Cohen-Solal. Isolation and characterization of the human 2,3-bisphosphoglycerate mutase gene. Journal of Biological Chemistry, 263(30):15785–15790, October 1988. URL: http://dx.doi.org/10.1016/s0021-9258(19)37657-4, doi:10.1016/s0021-9258(19)37657-4. This article has 15 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(19)37657-4)

[4. (Lemarchandel1992Compound) V Lemarchandel, V Joulin, C Valentin, R Rosa, F Galacteros, J Rosa, and M Cohen- Solal. Compound heterozygosity in a complete erythrocyte bisphosphoglycerate mutase deficiency. Blood, 80(10):2643–2649, November 1992. URL: http://dx.doi.org/10.1182/blood.v80.10.2643.2643, doi:10.1182/blood.v80.10.2643.2643. This article has 31 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood.v80.10.2643.2643)

[5. (Ravel1997Critical) Pascale Ravel, Constantin T. Craescu, Nicole Arous, Jean Rosa, and Marie Claude Garel. Critical role of human bisphosphoglycerate mutase cys22 in the phosphatase activator-binding site. Journal of Biological Chemistry, 272(22):14045–14050, May 1997. URL: http://dx.doi.org/10.1074/jbc.272.22.14045, doi:10.1074/jbc.272.22.14045. This article has 8 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.272.22.14045)

[6. (Rosa1989Isolation) R Rosa, Y Blouquit, M C Calvin, D Prome, J C Prome, and J Rosa. Isolation, characterization, and structure of a mutant 89 arg → cys bisphosphoglycerate mutase. Journal of Biological Chemistry, 264(14):7837–7843, May 1989. URL: http://dx.doi.org/10.1016/s0021-9258(18)83118-0, doi:10.1016/s0021-9258(18)83118-0. This article has 24 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(18)83118-0)

[7. (Lazana2020Uniparental) Ioanna Lazana, Azim Mohamedali, Frances Smith, Hugues de Lavallade, Donal McLornan, and Kavita Raj. Uniparental disomy (upd) of a novel bisphosphoglycerate mutase (bpgm) mutation leading to erythrocytosis. British Journal of Haematology, 192(1):220–223, November 2020. URL: http://dx.doi.org/10.1111/bjh.17223, doi:10.1111/bjh.17223. This article has 7 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/bjh.17223)

[8. (Chu2014Insights) Wen-Ting Chu, Qing-Chuan Zheng, and Hong-Xing Zhang. Insights into the phosphatase and the synthase activities of human bisphosphoglycerate mutase: a quantum mechanics/molecular mechanics simulation. Physical Chemistry Chemical Physics, 16(9):3946, 2014. URL: http://dx.doi.org/10.1039/c3cp53935k, doi:10.1039/c3cp53935k. This article has 5 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1039/c3cp53935k)

[9. (Aljahdali2022Molecular) Anfal S. Aljahdali, Faik N. Musayev, John W. Burgner, Mohini S. Ghatge, Vibha Shekar, Yan Zhang, Abdelsattar M. Omar, and Martin K. Safo. Molecular insight into 2-phosphoglycolate activation of the phosphatase activity of bisphosphoglycerate mutase. Acta Crystallographica Section D Structural Biology, 78(4):472–482, March 2022. URL: http://dx.doi.org/10.1107/s2059798322001802, doi:10.1107/s2059798322001802. This article has 4 citations.](https://doi.org/10.1107/s2059798322001802)